Millennium Management LLC purchased a new position in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 367,989 shares of the company's stock, valued at approximately $1,332,000. Millennium Management LLC owned 0.44% of Atyr PHARMA at the end of the most recent quarter.
Several other institutional investors have also added to or reduced their stakes in the business. Federated Hermes Inc. bought a new position in Atyr PHARMA in the fourth quarter worth approximately $53,093,000. Tikvah Management LLC bought a new position in Atyr PHARMA in the fourth quarter worth approximately $8,908,000. Alyeska Investment Group L.P. bought a new position in Atyr PHARMA in the fourth quarter worth approximately $4,628,000. Adage Capital Partners GP L.L.C. bought a new position in Atyr PHARMA in the fourth quarter worth approximately $3,620,000. Finally, Geode Capital Management LLC bought a new position in Atyr PHARMA in the fourth quarter worth approximately $3,229,000. 61.72% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on ATYR. Leerink Partners began coverage on shares of Atyr PHARMA in a research note on Tuesday, February 18th. They issued an "outperform" rating and a $16.00 price objective for the company. HC Wainwright reissued a "buy" rating and issued a $35.00 price objective on shares of Atyr PHARMA in a research note on Wednesday. Finally, Leerink Partnrs raised shares of Atyr PHARMA to a "strong-buy" rating in a research note on Tuesday, February 18th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $18.60.
Check Out Our Latest Stock Report on Atyr PHARMA
Atyr PHARMA Price Performance
ATYR traded up $0.03 during trading on Friday, hitting $5.38. 2,577,808 shares of the company traded hands, compared to its average volume of 1,009,962. The company has a market cap of $478.84 million, a PE ratio of -5.72 and a beta of 0.88. The stock's 50-day simple moving average is $3.49 and its two-hundred day simple moving average is $3.52. Atyr PHARMA INC has a 1 year low of $1.42 and a 1 year high of $5.75. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02.
Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.02. As a group, sell-side analysts anticipate that Atyr PHARMA INC will post -0.91 earnings per share for the current fiscal year.
About Atyr PHARMA
(
Free Report)
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
See Also
Before you consider aTyr Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and aTyr Pharma wasn't on the list.
While aTyr Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
